Locus Biosciences
PrivateLast Round
Grant
Jan 7, 2026
Total Funding Raised
$142.88M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Locus Biosciences is a biotechnology company that develops engineered bacteriophage-based products aimed at precisely eliminating pathogenic bacteria from the human body through the innovative use of CRISPR-Cas3 technology and safe delivery systems.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Locus Biosciences Comparables
Compare Locus Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SNIPR Biome | 87% | |
| Eligo Bioscience | 87% | |
| BiomX Inc. | 85% |
Locus Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 7, 2026 | ||||
| Grant | Jan 23, 2024 | ||||
| Series B | May 18, 2022 | ||||
| Debt | Oct 19, 2021 | ||||
| Grant | Nov 10, 2020 | ||||
Corporate Funding | Sep 30, 2020 |
Key People
Founding team and executive leadership
Locus Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hercules Capital | Debt |
| National Institute of Allergy and Infectious Diseases | Grant |
| CARB-X | Grant |
| ARTIS Ventures | Series B, Series A |
| Public Health Emergency Medical Countermeasures Enterprise | Grant, Corporate Funding |
| Abstract Ventures | Series A |
| Viking Global Investors | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 7, 2026
$24M grant awarded by BARDA and PHME.
- Oct 28, 2025
Developing therapies for ophthalmic bacterial infections with Viatris.
Recent news
Latest coverage and updates
- is_developingAug 12, 2026
Locus Biosciences, Inc. is developing engineered bacteriophages that selectively eliminate antibiotic-resistant E. coli.
Locus Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Locus Biosciences's valuation, stock price, and market status.
Is Locus Biosciences a public or private company?
Locus Biosciences is a private company.
What is the current stock price of Locus Biosciences?
Locus Biosciences is a private company with no public stock price. No recent secondary market data is available.
How much is Locus Biosciences worth (valuation)?
Valuation information for Locus Biosciences is not publicly available.
Can I buy Locus Biosciences stock?
Locus Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Locus Biosciences's last funding round?
Locus Biosciences's most recent funding round was Grant on January 23, 2024.
Who are the main investors in Locus Biosciences?
Key investors in Locus Biosciences include ARTIS Ventures, Viking Global Investors, Johnson & Johnson Innovation - JJDC, Inc..
Will Locus Biosciences IPO soon?
No public IPO plans have been announced for Locus Biosciences.
How can I track Locus Biosciences secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Locus Biosciences's secondary market activity and sign up for updates.